Rapid Clinical and Radiologic Responses With Larotrectinib Treatment in a Patient With TRK-Fusion-Positive Metastatic Lung Cancer

Clin Lung Cancer. 2020 Mar;21(2):e49-e53. doi: 10.1016/j.cllc.2019.11.010. Epub 2019 Nov 20.

¹ Department of Respiratory and Critical Care Medicine, Karl Landsteiner Institute of Lung Research and Pulmonary Oncology, Krankenhaus Nord, Vienna, Austria. Electronic address: maximilian.hochmair@wienkav.at.
² Department of Pathology, Wilhelminenspital, Vienna, Austria.
³ Department of Pathology, Wilhelminenspital, Vienna, Austria; Department of Pathology, Klinik Floridsdorf, Krankenhaus Nord, Vienna, Austria.
⁴ Department of Respiratory and Critical Care Medicine, Karl Landsteiner Institute of Lung Research and Pulmonary Oncology, Krankenhaus Nord, Vienna, Austria.
⁵ Department of Thoracic Surgery, Klinik Floridsdorf, Krankenhaus Nord, Vienna, Austria.
⁶ Institute of Pathology, Medical University of Vienna, Vienna, Austria.
⁷ Department of Biomedical Imaging and Image-Guided Therapy, Medical University of Vienna, Vienna, Austria; Department of Radiology and Cancer Research UK, Cambridge, England, UK.

No abstract available

Keywords: Case report; Entrectinib; Rare oncogenic driver; TRK inhibition; Tropomyosin receptor kinase fusion.

Publication types